Similar articles

• Bills target biosimilar drugs.

  Wadman M. Wadman M. Nature. 2009 Mar 26;458(7237):394-5. doi: 10.1038/458394b. Nature. 2009. PMID: 19325595 No abstract available.
• Path to approval proves rocky for copycat biodrugs.

  Wadman M. Wadman M. Nature. 2005 Nov 10;438(7065):154-5. doi: 10.1038/438154a. Nature. 2005. PMID: 16281004 No abstract available.
• Generics battle brand names over mortality of drug patents.

  Betz R. Betz R. J Healthc Resour Manag. 1995 Jul;13(7):35-7. J Healthc Resour Manag. 1995. PMID: 10144008 No abstract available.
• [Similarity of biotechnology-derived drugs: regulatory framework and specificity].

  Prugnaud JL. Prugnaud JL. Ann Pharm Fr. 2008 Aug;66(4):206-11. doi: 10.1016/j.pharma.2008.07.008. Epub 2008 Sep 9. Ann Pharm Fr. 2008. PMID: 18847566 Review. French.
• Follow-on biologics: data exclusivity and the balance between innovation and competition.

  Grabowski H. Grabowski H. Nat Rev Drug Discov. 2008 Jun;7(6):479-88. doi: 10.1038/nrd2532. Epub 2008 May 12. Nat Rev Drug Discov. 2008. PMID: 18469828 Review.